Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

INO

Live52w low +30.1%

Annual Quarterly

Core line items from INO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: INOVIO PHARMACEUTICALS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$404.00K	$0.00	$65.34K	$65.34K	$65.34K
Operating Income	Not available	$-21.95M	$-86.82M	$-69.35M	$-48.14M
Net Income	Not available	$-19.68M	$-84.95M	$-88.71M	$-23.52M
EPS (Diluted)	$-0.26	$-0.28	$-1.81	$-2.12	$-1.12
Total Assets	Not available	$49.78M	$74.31M	$69.39M	$68.24M
Total Liabilities	Not available	$43.71M	$50.21M	$77.11M	$39.71M
Cash & Equivalents	Not available	$26.27M	$44.27M	$36.57M	$24.35M
Free Cash Flow OCF − CapEx	Not available	$-21.59M	$-88.92M	$-69.42M	$-47.78M
Shares Outstanding	Not available	69.77M	69.00M	53.57M	36.72M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from INO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +30.1%

Entity: INOVIO PHARMACEUTICALS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$404.00K	$0.00	$65.34K	$65.34K	$65.34K
Operating Income	Not available	$-21.95M	$-86.82M	$-69.35M	$-48.14M
Net Income	Not available	$-19.68M	$-84.95M	$-88.71M	$-23.52M
EPS (Diluted)	$-0.26	$-0.28	$-1.81	$-2.12	$-1.12
Total Assets	Not available	$49.78M	$74.31M	$69.39M	$68.24M
Total Liabilities	Not available	$43.71M	$50.21M	$77.11M	$39.71M
Cash & Equivalents	Not available	$26.27M	$44.27M	$36.57M	$24.35M
Free Cash Flow OCF − CapEx	Not available	$-21.59M	$-88.92M	$-69.42M	$-47.78M
Shares Outstanding	Not available	69.77M	69.00M	53.57M	36.72M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.